Pricing Log in Create free account
Friday 6 November 2026 Export IDXX’s income statement to Excel — free account

IDEXX Laboratories, Inc.

IDXX Healthcare Diagnostics & Research

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.

Revenue
+9.86%
EPS
+17.3%
Free cash flow
+17.6%
Total debt
−28.6%

Quarter to September 2026, against a year earlier

677.66 6.95 +1.04%
Market cap
$52.8B
P/E
44.8×
Fwd P/E
37.3×
Dividend yield
—
F-score
8/9
Altman Z
24.09
Beneish M
−2.50
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

IDEXX Laboratories, Inc. 10-Q filed Aug 4, 2025

Fiscal Q2 2025 · Period ended Jun 30, 2025 · Filed · accepted 4:22 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 1, 2025: 33 added · 5 removed · 40 modified; 5 with only figures updated; 3 moved without change

  1. Modified

    Any forward-looking statements represent our estimates only as of the day this Quarterly Report on Form 10-Q was filed with the SEC and should not be relied upon as representing our estimates as of any subsequent date. From time to time, oral or written forward-looking statements may also be included in other materials released to the public, and they are subject to the riskrisks and uncertainties described or cross-referenced in this section. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates or expectations change.